Stockwinners Market Radar for March 24, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:07 EDT GameStop director buys $195K in common stock - In a regulatory filing, GameStop disclosed that its director Alain Attal bought 1.5K shares of common stock on March 24th in a total transaction size of $194.9K.

18:16 EDT Citizens Financial's acquisition of Investors Bancorp approved - Citizens Financial (CFG) ("Citizens") and Investors Bancorp (ISBC) received regulatory approval from the Board of Governors of the Federal Reserve System and the Office of the Comptroller of the Currency to complete the acquisition of Investors. The acquisition is anticipated to close by mid-April, pending satisfaction of customary closing conditions. After closing, over the course of 2022, Citizens will provide Investors' customers with comprehensive information relating to the anticipated conversion of their accounts to Citizens, targeted to be completed in 1Q23. Until conversion, customers will continue to be served through their respective Citizens and Investors branches, websites and mobile applications. Members of Investors' management team are expected to join Citizens. Upon closing of the transaction, Mr. Cummings and Michele N. Siekerka, who currently serve on the board of directors of Investors, are expected to join Citizens' board of directors. Domenick Cama, Investors' President and COO, will join Citizens as the New York City and New Jersey Market President and Co-Head of Integration.

17:40 EDT Shaw says CRTC approves transfer of broadcasting undertakings to Rogers - Shaw Communications (SJR) said the Canadian Radio-television and Telecommunications Commission's, CRTC, comprehensive review and approval of the transfer of Shaw's licensed broadcasting undertakings to Rogers Communications (RCI) marks an important milestone towards both companies combining successfully. Brad Shaw, Executive Chair & CEO of Shaw commented on today's ruling: "We appreciate the CRTC's thoughtful inquiry and remain committed to working with government and regulators to achieve a successful completion of our proposed transaction with Rogers. "Today's announcement is a critical milestone in the journey we are taking towards all regulators approving the combination of our two companies. Our team is continuing to work toward completing the thorough regulatory reviews that remain underway to deliver our shareholders the value they expect to receive upon closing, expected to be in the first half of 2022," he added.

17:33 EDT Moody's withdraws credit ratings on Russian entities - Moody's announced that Moody's Investors Service - MIS - intends to withdraw its credit ratings on Russian entities. On March 5, Moody's announced the suspension of commercial operations in Russia.

17:24 EDT Power Integration opens $20M facility in Biel, Switzerland, housing SMT line - Power Integrations opened its newly constructed facility in Biel, Switzerland at a ceremony hosted by the company's CEO, Balu Balakrishnan, and attended by Biel mayor Erich Fehr. The 4,600-square-meter, $20M facility is the new home for about 60 engineers and other technology professionals, a number that is expected to rise as the company continues to grow in the years ahead. In addition to modern office and laboratory space, the contemporary building houses a surface-mounted-technology line used to develop prototypes for the company's gate-driver products. The facility also features a 25-kilowatt rooftop solar array.

17:04 EDT Netflix says Boss Fight Entertainment joins company, terms not disclosed - Netflix announced that Boss Fight Entertainment is joining Netflix. Boss Fight Entertainment was founded in 2013 by David Rippy, Bill Jackson, and Scott Winsett. "Boss Fight's mission is to bring simple, beautiful, and fun game experiences to our players wherever they want to play," said the founders of Boss Fight Entertainment. "Netflix's commitment to offer ad-free games as part of members' subscriptions enables game developers like us to focus on creating delightful game play without worrying about monetization. We couldn't be more excited to join Netflix at this early stage as we continue doing what we love to do while helping to shape the future of games on Netflix together."

17:00 EDT Diamond Offshore announces relisting on NYSE - Diamond Offshore Drilling announced that the company has received approval to relist its unrestricted common stock on the New York Stock Exchange under the ticker symbol "DO." The company expects the common stock to commence trading on or about Wednesday, March 30, 2022. Bernie Wolford, Jr., President and Chief Executive Officer, stated, "We are excited to return to the public markets on the NYSE. The relisting of our common stock is another important step in strengthening our capital structure to position Diamond for long-term success and growth."

16:37 EDT Flowserve enters into partnership with Gradiant on water treatment - Flowserve announced it has entered into a non-exclusive partnership agreement with Gradiant to help address the most challenging problems in water and wastewater treatment. CEO Scott Rowe says: "This new partnership with Gradiant not only strengthens Flowserve's commitment and offering to the water market, but it also supports our sustainable development goals to make the world better for everyone."

16:32 EDT KBR, Exxon Mobil Catalysts and Licensing to collaborate on PDH technology - KBR (KBR) and ExxonMobil Catalysts and Licensing (XOM) will collaborate to bring advancements to propane dehydrogenation, or PDH, technology. Under the collaboration, ExxonMobil's new proprietary catalyst technology will be combined with KBR's proprietary K-PRO PDH technology to convert propane into propylene. Enabled by the performance of ExxonMobil's new catalyst, the combined technology solution could offer financial savings compared to PDH technologies currently available.

16:31 EDT Titan International enters three-year agreement with CNH Industrial - Titan International (TWI) and CNH Industrial (CNHI) have entered into a three-year agreement to supply farm wheels and tires manufactured in Titan's North America, South America and European plants to various CNH Industrial manufacturing locations. The value of the contract considering today's dollars and current raw material pricing levels, is expected to approximate $400M.

16:23 EDT Perrigo announces planned retirement of CFO Ray Silcock - Perrigo announced the planned retirement of Ray Silcock, Executive Vice President and CFO, who will remain with the company in his current position until July 15. The company has initiated a comprehensive search with the assistance of a leading executive search firm to identify a successor for this position.

16:19 EDT Mister Car Wash jumps over 3% to $16.39 after Q4 earnings beat

16:08 EDT Floor & Decor launches grand opening of North Portland, OR store on March 31 - Floor & Decor will expand its nationwide footprint when it opens the doors to its newest location in North Portland, Oregon on March 31, 2022. The 79,000 square-foot Floor & Decor warehouse store and design center will open with a team of about 50 full-time and part-time associates led by Sarah Valentine, the new store's Chief Executive Merchant. "Floor & Decor is excited to open a store in North Portland," said Valentine. "We are eager to introduce both Professional customers, as well as Homeowners, to our one-stop solution for their flooring needs with an extensive selection of in-stock, trend-right flooring options. We offer great service and quality flooring at unbeatable prices. With our free design services, we look forward to helping every customer turn their vision into reality."

16:08 EDT Sight Sciences announces first patient treated in TRIDENT trial - Sight Sciences announced that the first patient has been treated in the novel TRIDENT clinical trial, designed to demonstrate the Omni Surgical System with higher volume as a safe and effective standalone treatment option, compared to implantation of iStent inject, in lowering IOP in adult patients with open-angle glaucoma. With glaucoma, elevated IOP is the leading risk factor for the development and progression of the disease.

16:06 EDT Izea Managed Services bookings tops $11.5M in Q1 to date - IZEA Worldwide announced that it has set a new all-time record for quarterly Managed Services bookings. Managed Services bookings for the first quarter to date have surpassed $11.5M, compared with $6.45M in Q1 2021, an increase of over 80% year over year. IZEA has surpassed the previous quarterly Managed Services bookings record of $11.3M, set in Q3 of 2021. "We have seen a significant positive progression in Managed Services bookings showing a recovery following the initial onset of COVID-19 in March of 2020," said Ted Murphy, IZEA Founder and CEO. "Our focus on providing the highest quality service to our customers is being rewarded with both new contracts and expansion of existing relationships. IZEA continues to show positive momentum with Managed Services bookings in the month of March despite the environment of global financial and geopolitical challenges."

16:06 EDT SmartRent acquires SightPlan for about $135M in all-cash transaction - SmartRent announced the acquisition of SightPlan, a player in multifamily workflow management. The acquisition advances SmartRent's product roadmap and augments the breadth of cloud-based SaaS solutions for current and prospective customers, creating a comprehensive property and resident management platform. "We are excited about bringing SightPlan on to the SmartRent platform; the alignment of our open-API solutions creates a powerful combination for real estate operators," said Lucas Haldeman, CEO of SmartRent. "Our organizations share similar values and have a deep passion for helping people live easier, better lives. Combining our highly complementary product offerings enables us to deliver enhanced experiences for residents, property owners, and managers, and increases our competitive advantage. We know the SightPlan team well and are excited to welcome them to the SmartRent family." SmartRent acquired 100% of the equity interests of SightPlan on March 22, 2022, for approximately $135M in an all-cash transaction. The SightPlan team will join SmartRent as employees, and SightPlan will continue to run its operations from its Orlando, Florida office. SightPlan's customer subscriptions are expected to add approximately $10M to SmartRent's SaaS revenue for 2022. Software Equity Group served as the exclusive advisor to SightPlan on the transaction.

16:03 EDT MEI Pharma, Kyowa Kirin won't submit FDA marketing application on TIDAL study - MEI Pharma and Kyowa Kirin provided an update after a recent meeting with the U.S. Food Drug Administration to discuss the pursuit of a marketing authorization for zandelisib, a phosphatidylinositol-3-kinase inhibitor drug candidate, via the accelerated approval pathway under 21 CFR Part 314.500, Subpart H, based on data generated by the single arm Phase 2 TIDAL study. In the meeting, the FDA informed the companies of its position that a randomized trial is now needed to adequately assess drug efficacy and safety of PI3K inhibitor drug candidates, including zandelisib. Based on this view, the agency discouraged a filing based on the Phase 2 TIDAL study data and emphasized that the companies continue efforts with the ongoing, randomized Phase 3 COASTAL study as planned. Accordingly, in line with the FDA's recommendation, the companies do not plan to submit an FDA marketing application based on the single arm Phase 2 TIDAL study. In addition, while the FDA stated that safety on the 60 mg intermittent schedule appears reasonable, it recommended continued dose exploration to further support the current dose and regimen. "The FDA's current position on the assessment of benefit and risk of PI3K inhibitors solely based on single arm studies appears to have evolved, as evidenced by the position the FDA communicated at the recent meeting on zandelisib, and the upcoming ODAC meeting scheduled for April 21, 2022 to discuss whether randomized data should be required for the class of PI3K inhibitors to demonstrate appropriate evidence of efficacy and safety," said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma. "Clearly, the outcome of our recent FDA meeting is a disappointing development. Nonetheless we will continue to focus on the ongoing Phase 3 COASTAL study as we consider options that provide the most expeditious approval pathway utilizing randomized data, and which we believe will demonstrate the potential of zandelisib to help patients. Today's announcement in no way diminishes our conviction to the development of zandelisib and the promise of its emerging clinical profile. Based on current projections, MEI believes we have sufficient cash for operations to complete the COASTAL study enrollment in 2024." Dr. Gold continued: "In partnership with Kyowa Kirin, we remain committed to the ultimate potential of zandelisib to address important medical needs as a single agent or in combination with other therapies providing physicians, and their patients, important new treatment options. We plan on completing evaluation of the Phase 2 TIDAL study, and look forward to sharing final data later this year to further advance an understanding of zandelisib's clinical utility." "Our dialogue with the FDA has updated our understanding of the evolving regulatory view of the PI3K inhibitor drug class. With this knowledge, we can focus our efforts to advance the COASTAL program," said Yoshifumi Torii, Ph.D., Executive Officer, Vice President, Head of R&D of Kyowa Kirin. "Our teams around the world have made steady progress to enroll patients and give us important momentum. Together with MEI Pharma, we will continue to work with the investigators, patients, and advocacy organizations to drive continued progress."

15:38 EDT Exxon Mobil to make no new investments in Russia, says complying with sanctions - Exxon Mobil issued the following statement on its website: "ExxonMobil supports the people of Ukraine as they seek to defend their freedom and determine their own future as a nation. We deplore Russia's military action, which has violated Ukraine's territorial integrity and endangered its people. In response to recent events, we are working to discontinue operations and taking steps to exit the Sakhalin-1 project. For more than 20 years we have operated the Sakhalin-1 project on behalf of an international consortium of Japanese, Indian and Russian companies. As part of the process to discontinue operations, we will work to carefully manage our exit operations while ensuring safety and environmental protection. Given the current situation, ExxonMobil will make no new investments in Russia and is also fully complying with all sanctions." Reference Link

15:14 EDT Asana down 6% in afternoon trading - Shares of Asana are down $2.62, or 6%, to $41.56. Earlier this afternoon, Jefferies analyst Brent Thill hosted Asana CEO Dustin Moskovitz for a webinar. Reference Link

14:48 EDT Reynolds American reducing U.S. manufacturing footprint by 2025 - Reynolds American said that as a part of its "effort to transform the company and position it for future growth," it recently concluded a detailed strategic review of its U.S. Operations and will be reducing its manufacturing footprint resulting in the closing of some sites. Guy Meldrum, President and CEO of Reynolds, said, "These decisions are never easy. We are focused on delivering long-term, sustainable growth in a rapidly evolving environment. While these changes are necessary to support the future of our business, they will be extremely difficult for our employees at the manufacturing sites that are closing and today we are focused on providing support to them through this transition." Beginning next month and progressing through 2024, the company has announced: Santa Fe Natural Tobacco Company's operations in Oxford, N.C. will move to Tobaccoville, N.C.; American Snuff Company's operations at Taylor Brothers in Winston-Salem, N.C. will move to Tobaccoville, N.C.; ASC's Traditional Oral operations in Memphis, Tenn., will move to Clarksville, Tenn. "More than half of employees across the closing facilities will have the opportunity to transfer sites," the company added. These changes will reduce its full-time employee workforce by approximately 350 roles by 2025. Reynolds American is an indirect, wholly-owned subsidiary of the BAT Group.

14:04 EDT AstraZeneca reports Evusheld recommended for approval in EU for COVID prevention - AstraZeneca's Evusheld, a long-acting antibody combination, has been recommended for marketing authorization in the European Union for the pre-exposure prophylaxis, or prevention, of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg, the company announced. Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: "Today's positive CHMP recommendation represents a significant step forward in our ongoing efforts to introduce additional, important preventative measures for people in Europe at higher risk of developing COVID-19. Evusheld has the potential to provide long-lasting protection to vulnerable populations such as the immunocompromised who can't mount an adequate response to a COVID-19 vaccine, and we'll continue to work with governments in Europe to make Evusheld available as quickly as possible." The recommended dose of Evusheld in Europe is 150mg of tixagevimab and 150mg of cilgavimab, administered as two separate sequential intramuscular injections.

13:32 EDT Medtronic announces first patient implants in TITAN 2 OAB study - Medtronic announced the first patient implants in the TITAN 2 pivotal study that will evaluate the safety and efficacy of Medtronic's investigational implantable tibial neuromodulation, or TNM, device in people with overactive bladder, or OAB. The minimally invasive technology stimulates the posterior tibial nerve near the ankle, transmitting electrical impulses that regulate neural activity of the bladder, the company noted. The TITAN 2 study is a prospective, multicenter, pivotal study to examine the safety and efficacy of the implantable TNM device in people with OAB. The study will include up to 130 patients from up to 30 sites in the U.S. The primary endpoint for the study is six months, and patients will be followed for 24 months. Launched in April 2021, the TITAN 1 feasibility study characterized the procedure for the implantable TNM device in subjects with bladder incontinence. Upon successful completion of TITAN 2, Medtronic will prepare its submission to the U.S. Food and Drug Administration for approval, the company said.

13:07 EDT Steel Dynamics says Miguel Alvarez to lead North American Metals Recycling - Steel Dynamics announced the transition of Miguel Alvarez to lead the company's North American Metals Recycling platform effective March 31, 2022, which will proceed the July 2022 retirement of Russell Rinn, the company's EVP of Metals Recycling since July 2011. Rinn will remain a valuable resource to the company in a consulting role until his retirement, continuing to report to the company's CEO. The company is also promoting James Anderson from his current position as Vice President of the company's steel fabrication operations to a Senior Vice President retaining the same responsibilities, also effective March 31, 2022.

13:00 EDT COVID pushed launch of TapouT but Splash saw 'no supply chain issues,' CEO says

13:00 EDT 'Distribution is everything,' Splash Beverage CEO tells The Fly

12:48 EDT ABB announces new share buyback program of up to $3B - ABB said it has completed its share buyback program that was launched in April 2021 as part of the company's commitment to return to shareholders cash proceeds from the Power Grids divestment of $7.8B. Through this buyback program, ABB repurchased a total of 90,066,100 shares - equivalent to 4.15% of its issued share capital at launch of the buyback program - for a total amount of approximately $3.1B over the past 12 months. ABB's board today approved a new share buyback program of up to $3B. As part of this program, the company intends to return to its shareholders the remaining $1.2B of the $7.8B of cash proceeds from the Power Grids divestment. The new program is expected to be launched in April. It will be executed on a second trading line on the SIX Swiss Exchange.

12:18 EDT Bayer's Monsanto settles with Ohio Attorney General for $80M - Ohio Attorney General Dave Yost announced an $80M settlement with the Monsanto that "forces the company to pay for the long-standing environmental damage it knowingly caused in Ohio with its toxic products." The state filed suit against Monsanto in 2018, maintaining that the company had known for decades that it created products with harmful levels of polychlorinated biphenyls. he company was purchased by Bayer in 2018 shortly after the state filed its lawsuit. Reference Link

12:02 EDT JetBlue, Qatar Airways plan to expand global partnership - JetBlue announced it intends to expand the depth and breadth of its existing partnership with Qatar Airways to offer customers even more benefits when booking travel to and from international destinations on the global partner airline. This will include more codesharing in additional markets in the coming months, enhanced benefits for JetBlue TrueBlue and Qatar Airways' Privilege Club loyalty members, expanded marketing opportunities and refinements to flight schedules to create new, convenient connections across both carriers. This new agreement will provide more options to travel between JetBlue's 100+ destinations across North America and the Caribbean and Qatar Airways global network of 82 countries. JetBlue places its code on Qatar Airways flights in - or offers connections through - nine U.S. gateways. In addition, the airlines plan to develop an integrated airside transfer option for customers connecting at New York-JFK, JetBlue's largest focus city and Qatar Airways' most served U.S. destination.

12:00 EDT Sonendo falls -11.5% - Sonendo is down -11.5%, or -63c to $4.85.

12:00 EDT Cleveland-Cliffs rises 10.9% - Cleveland-Cliffs is up 10.9%, or $3.17 to $32.33.

12:00 EDT SES rises 14.3% - SES is up 14.3%, or $1.19 to $9.50.

11:32 EDT EMA recommends AstraZeneca's Evusheld for COVID prevention - The European Medicines Agency's human medicines committee recommended granting a marketing authorization for Evusheld, developed by AstraZeneca, for the prevention of COVID-19 in adults and adolescents from 12 years of age weighing at least 40 kg before potential exposure to the SARS-CoV-2 virus. Evusheld is made of the active substances tixagevimab and cilgavimab, two monoclonal antibodies designed to attach to the spike protein of the SARS-CoV-2 virus at two different sites. The CHMP concluded that the medicine's benefits are greater than its risks in the approved use and will now send its recommendation to the European Commission for a "rapid decision" applicable in all EU Member States. []:[https://www.ema.europa.eu/en/news/ema-recommends-authorisation-covid-19-medicine-evusheld]

10:04 EDT Outbrain, Axel Springer enter cross-brand global partnership - Outbrain announced it had been selected by Axel Springer, Europe's leading digital publisher, to power its sponsored content recommendations. According to the agreement, the German digital offerings of the BILD and WELT Groups as well as B.Z., Rolling Stone, Musikexpress, and Metal Hammer will integrate Outbrain's recommendation technology to serve personalized editorial article recommendations and support Axel Springer's monetization with native advertising. BILD and WELT will start March 30, 2022, the other brands will follow shortly thereafter.

10:02 EDT CNH Industrial invests in advanced engineering center in Arizona - CNH Industrial has opened a new engineering center in Scottsdale, Arizona. This facility will support the growth of the company's Raven precision agriculture technology business as it develops customer solutions, CNH said in a statement. In addition to the new Scottsdale location, CNH Industrial also intends to invest in the expansion of Raven's existing Innovation Campus in Baltic, South Dakota, located minutes away from its Headquarters in Sioux Falls.

10:00 EDT GameStop falls -9.2% - GameStop is down -9.2%, or -$13.00 to $128.00.

10:00 EDT Traeger falls -18.4% - Traeger is down -18.4%, or -$1.61 to $7.18.

10:00 EDT Movado rises 13.3% - Movado is up 13.3%, or $4.61 to $39.18.

09:51 EDT Uber jumps after inking deal with Curb to list NYC taxis on app - Curb, a ride-hailing app for licensed taxi and for-hire rides, announced a strategic partnership agreement with Uber, enabling Curb-connected drivers to receive trip requests from Uber users. Curb and Uber's partnership will launch in New York City and will expand to Curb's nationwide network over the coming months. "The integration enables both companies to offer riders and drivers more flexibility and coverage as urban transportation ramps back up in major cities. Taxi drivers will have access to incremental trip offers from Uber on top of the millions of annual ride requests through the Curb app, while Uber users will have more ride options to meet their needs as they travel," the companies said in a statement. Riders in New York City will be able to book rides in Curb-connected taxis through the Uber app in addition to existing vehicle options provided by Uber. Shares of Uber are up 4%, or $1.20, to $34.27 in the morning trading.

09:47 EDT Spartan Acquisition III Corp trading resumes

09:47 EDT ReneSola falls -9.5% - ReneSola is down -9.5%, or -65c to $6.16.

09:47 EDT Movado rises 10.4% - Movado is up 10.4%, or $3.61 to $38.18.

09:47 EDT SES rises 13.2% - SES is up 13.2%, or $1.10 to $9.41.

09:41 EDT Spartan Acquisition III Corp trading halted, volatility trading pause

09:36 EDT Healthcare Capital Corp trading halted, volatility trading pause

09:30 EDT Screen Media, BBC Studios sign multi-year content deal - Chicken Soup for the Soul Entertainment announced a multi-year content deal with BBC Studios that will bring more than 2,500 hours of premium content to all current and future Crackle Plus streaming services including Crackle, Popcornflix, and Chicken Soup for the Soul. Crackle Plus, also a Chicken Soup for the Soul Entertainment company, is one of the largest operators of streaming advertising-supported video-on-demand networks. This announcement comes on the heels of another major deal between the two sides that saw the exclusive rights to the popular series Sherlock go to Crackle Plus. More than 300 hours of content will be available to viewers for free on various Crackle Plus streaming services beginning in April. This includes the award-winning, critically acclaimed mystery series Ripper Street, starring Matthew MacFadyen, several seasons of which will be streaming only on Crackle Plus. In addition, A Life in Ten Pictures will have its exclusive U.S. premiere in June on Crackle Plus. More content will be added each month throughout the multi-year agreement.

09:24 EDT Curtiss-Wright Laser Peening process gets verifcation for 5th gen F-35 fighter - Curtiss-Wright announced the successful verification of the Curtiss-Wright Laser Peening process on the airframe components of the fifth-generation F-35 fighter jet. Curtiss-Wright has been selected to help extend the life expectancy of the F-35B, the short takeoff-vertical landing STOVL variant flown by the U.S. Marine Corps and other allied nations around the world, by utilizing its critical Laser Peening process. The verification was implemented by the Fleet Readiness Center East FRCE at the Marine Corps Air Station Cherry Point, NC and the first F-35B to undergo the treatment has been successfully returned to the fleet. "Curtiss-Wright is honored to be part of this milestone through the utilization of our critical surface treatment applications, building on our commercial and industrial capabilities to support the military's premier fighter jet program," said Lynn M. Bamford, President and CEO of Curtiss-Wright Corporation. "We are excited to be part of the team that returned the first laser peened F-35B back to active service, and we look forward to a long and successful relationship with all of the stakeholders involved on other F-35 variants." The verification marks FRCE as the first facility in the world capable of conducting on-site laser peening modification on an F-35 aircraft. A second facility, Ogden Air Logistics Complex at Hill Air Force Base, Utah, is now also fully operational and the first F-35B will be processed at that facility starting in April of 2022, followed shortly thereafter by the F-35C.

09:17 EDT E2open CFO Jarett Janik to retire - E2open announced that Jarett Janik will retire from his position as chief financial officer. He will continue serving as CFO until the company identifies his successor. E2open has initiated an external search for a new chief financial officer and Janik has agreed to stay with the company through the transition process. He joined E2open in April 2018, having served in various senior finance and CFO roles in the technology space for more than 25 years.

09:13 EDT Altice USA, T-Mobile broaden MVNO pact, T-Mobile continues with mobile service - Altice USA (ATUS) and T-Mobile (TMUS) have expanded a multi-year MVNO agreement through which T-Mobile will continue to serve as the nationwide network for Altice USA's Optimum Mobile service. Terms of the new agreement are mutually beneficial to both companies. "As we continue to grow and evolve our Optimum Mobile service, we are pleased to reach a new agreement with T-Mobile that ensures our mobile customers will continue to benefit from T-Mobile's nationwide network," said Matt Marino, Executive Vice President of Consumer Services for Altice USA. "In addition to access to America's largest 5G network, the agreement enables Optimum Mobile to provide more flexibility and value to our customers and, when coupled with our Optimum and Suddenlink broadband service, deliver a 360-degree seamless connectivity experience at home and on the go." "We are excited to extend and expand our Altice USA partnership on the T-Mobile network with fast and reliable service to Altice USA's Optimum Mobile subscribers," said Daniel Thygesen, Senior Vice President of T-Mobile Wholesale. "By leveraging T-Mobile's unparalleled network and platforms to serve Optimum Mobile subscribers, Altice USA remains the premier one-stop-shop for bundled mobile and broadband services for its subscribers."

09:08 EDT Poland's National Institute of Cardiology uses Stereotaxis' Genesis RMN system - Stereotaxis announces that Poland's National Institute of Cardiology has established the first robotic electrophysiology program in the country with Stereotaxis' Genesis Robotic Magnetic Navigation system. The National Institute of Cardiology is the only hospital in Poland offering advanced robotic technology to improve the minimally invasive treatment of heart arrhythmias.

09:07 EDT Quotient Technology's current CTO Matthew Krepsik to be CEO by year-end 2022 - Quotient Technology announced that its Board of Directors has implemented a series of actions consistent with its commitment to shareholder value creation. Matthew Krepsik, currently Chief Technology Officer, will assume office as Quotient's next Chief Executive Officer by year-end 2022. Krepsik will succeed Steven Boal, who has served as CEO since August of 2019, when he returned to execute a turn-around of the business and will be stepping down at the time of the transition. Krepsik commented, "I am honored that I will become the next CEO of Quotient when Steven steps down. I am looking forward to building on the strong foundation we have in place to enhance our customer and partner experiences. Together with our talented team, we will continue to execute our strategy, developing new compelling capabilities and building valuable partnerships to lead the industry forward. I am excited to work with the Board and the entire Quotient team as we capture the significant

09:06 EDT WISeKey, Turing Crypto start joint sales operations of cybersecurity - WISeKey International and Turing Crypto announced the official start of operations and the generation of the first revenue and positive acceptance of new customers. Both companies signed a strategic partnership agreement to generate revenue and new technology offering. As per the terms of this agreement, WISeKey and Turing Cryptography have joined forces to roll out a full suite of TuringSign SSL/TLS services in the Asia-Pacific region secured by the OISTE/WISeKey Root of Trust. Turing Cryptography is a subsidiary of CrossCert. In subsequent phases, partners aim to expand the cooperation by offering complementary solutions, including Turing Cryptography's leading FIDO biometric authentication software and WISeKey's end-to-end Cybersecurity and IoT platform. The objective of the partnership is to generate synergies by launching new and innovative cryptographic security solutions in the Asia Pacific region and other markets. During phase one of this partnership, both partners have agreed to roll out SSL/TSL products in the Asia Pacific region. Future synergies are expected to include joint offerings in AI powered security solutions, where both companies possess core competencies. During the first quarter of 2022, commercial operations have ramped-up, with the initial launch in Korea and immediate plans to extend operations to Singapore, Hong-Kong, and Taiwan, and a next phase that aims a global reach. "We are pleased with the positive outcome of this strategic partnership, which will allow CrossCert Group and WISeKey to develop a growing business and offer their new combined technologies to a larger customer base. We have already identified new collaboration areas to extend our alliance and develop the IoT and NFT markets," said Carlos Moreira, Founder and CEO of WISeKey.

09:06 EDT Abbott's its FreeStyle Libre system gains expanded reimbursement in Japan - Abbott announced that the Japanese Ministry of Health, Labour and Welfare has approved the expansion of reimbursement coverage for its FreeStyle Libre system to include all people with diabetes who use insulin at least once a day. The expanded coverage will enable more people with diabetes to access the glucose data needed to manage their condition without the routine fingersticks1 associated with traditional blood glucose monitoring. The reimbursement expansion, which will go into effect April 1, was granted based on FreeStyle Libre's overall value proposition, which includes ease of use and scientific evidence that shows the clinical benefits of using the FreeStyle Libre system among all people who take self-injections of insulin.

09:05 EDT VerifyMe wins contract with international product inspection technology company - VerifyMe have signed an agreement with a premier international product security company that specializes in product authentication and mobile inspection systems. VerifyMe will provide its proprietary invisible ink, its patented mobile phone authentication device, and a custom mobile app to authenticate and decode covert variable codes to detect counterfeit and diverted products for this security company's client. The security company will provide VerifyMe's mobile phone authentication equipment to brand inspectors of a global consumer products company that is applying VerifyMe's variable invisible ink technology on labels and packaging. Revenue will be recognized based on the discretionary annual usage by the security company's client which VerifyMe currently expects will be at least 500,000 units annually.

09:04 EDT Lucid Group expands presence in Canada, sees Canadian deliveries in Spring 2022 - Lucid Group announced the official opening of its newest Studio location at the Yorkdale Shopping Centre in Toronto, Ontario. This location serves as the second location in Canada and 23rd in the company's growing North American retail network. The company expects to begin Canadian deliveries of the Lucid Air in Spring 2022. Lucid has collaborated with Electrify Canada to offer those who reserve a Lucid Air by June 30, 2022, two years of complimentary charging on the rapidly growing charging network. Designed to Combined Charging System standards and compatible with any open DC fast charging station, the Lucid Air Grand Touring is capable of the fastest charging speeds of any production car available today.

09:04 EDT Marrone Bio signs agreement with Corteva Agriscience - Marrone Bio Innovations (MBII) has signed an agreement with Corteva Agriscience (CTVA) that expands the opportunity for MBI technologies to be used on seeds sold by Corteva for row crops globally. Marrone Bio currently provides seed treatment solutions to Corteva for use throughout Europe. "Expanding our global cooperation with Corteva affirms the strength of the partnership we have developed over the last two years," states Kevin Helash, chief executive officer of Marrone Bio. "This new collaboration solidifies both companies' commitment to provide growers with efficacious and sustainable solutions that enhance crop productivity and return on investment." The agreement is effective immediately.

09:02 EDT Surgalign announces new data on SImmetry Sacroiliac Joint Fusion system - Surgalign announced the publication of results from EVoluSIon, EVSI, a large, prospective, multi-center study of clinical outcomes following minimally invasive sacroiliac joint, SIJ, fusion with decortication. Published in the February 2022 issue of the International Journal of Spine Surgery, Clinical Outcomes Following Minimally Invasive Sacroiliac Joint Fusion with Decortication: The EVoluSIon Clinical Study, reports 12-month clinical outcomes following minimally invasive SIJ fusion using the SImmetry Sacroiliac Joint Fusion system to treat SIJ dysfunction. With 250 patients and 23 sites participating, EVSI is one of the largest SIJ fusion studies conducted to date. The 12-month results from EVSI demonstrated statistically significant improvements in both pain and disability, along with a statistically significant reduction in the number of patients using opioids. More specifically, 72.2% of patients achieved the minimal clinically important difference, MCID, criteria of reduction in VAS, a measure of pain; 62.5% of patients achieved the MCID criteria of reduction in ODI, a measure of disability; 57.1% of patients reported cessation of opioid use; and 68.7% achieved radiographic fusion. These results compare favorably to published competitive data2,3,4,5 and are consistent with prior SImmetry publications. Surgalign is only the second company to report data on a study of this scale to offer a procedural solution with statistically significant data for SIJ fusion.

09:01 EDT Autodesk to acquire The Wild, terms not disclosed - Autodesk has announced it has signed a definitive agreement to acquire The Wild, a cloud-connected, extended reality platform, which includes its namesake solutions, The Wild, and IrisVR. The Wild enables architecture, engineering, and construction professionals to present, collaborate and review projects together in immersive and interactive experiences, from anywhere and at any time. This acquisition enables Autodesk to meet increasing needs for augmented reality and virtual reality technology advancements within the AEC industry and further support AEC customers throughout the project delivery lifecycle.

08:48 EDT Aptevo Therapeutics sees sufficient cash for at least the next 12 months - Aptevo had cash and cash equivalents as of December 31, 2021 totaling $46.3 million, including restricted cash of $1.3 million. The restricted cash is expected to be released over the next twelve months.

08:42 EDT RenovaCare announces resignations of interim President, CEO Nedd, CFO Frere - RenovaCare announced reductions in its management team to further streamline administrative expenses. On March 24, Dr. Kaiyo Nedd resigned as Interim President, Chief Executive Officer, CEO, and Director, and Justin Frere as Chief Financial Officer, CFO, and Secretary. Their resignations were not due to any disagreements between the Company and them on any matter relating to the Company's operations, policies, or practices. Dr. Nedd will continue to provide ongoing support to the Company as needed with respect to legacy matters, and Frere will continue to provide accounting services to the Company as needed. Chairman and majority stockholder, Harmel Rayat, will assume the roles of President, Chief Executive Officer, Chief Financial Officer and Secretary on an interim basis.

08:40 EDT Bridgeline Digital selected by landscaping supplier for its technology - Bridgeline Digital announced that their Hawksearch product has been chosen by a landscaping supplier to power their eCommerce site. The landscaping distributor chose Hawksearch to provide a search solution for their catalog in multiple languages. Ari Kahn, CEO of Bridgeline says, "Our commitment to providing best in class language capabilities allows our partners the ability to overcome language barriers and grow internationally. We're excited our partner has recognized our innovations and look forward to supporting their ability to increase revenue."

08:37 EDT ReShape announces momentum of DTC marketing campaign for Lap-Band - ReShape Lifesciences announced continued momentum in its national, direct-to-consumer marketing campaign, culminating in substantial increases in visits to Lapband.com, patients requesting additional information and scheduled doctor consultations. Since the beginning of the marketing campaign, in October 2021, the Company has experienced 250,000 more patient visits to the website, Lapband.com, resulting in over 900% more patient requests for information on the Lap-Band procedure, compared to pre-launch of the DTC marketing campaign. Importantly, doctor referrals for consultations have also surged nearly 400%. Throughout March, the Lap-Band is being featured in ten major publications and over 20 national cable stations. The company is also engaging in additional co-op marketing partnerships, local digital media and a national social media influencer campaign.

08:35 EDT Manhattan Associates' Active Omni chosen by New Look - Manhattan Associates announced that British fashion brand, New Look, has chosen Manhattan Active Omni as part of a strategic move. The Manhattan Active Omni suite will provide New Look with a single view of inventory across all customer touchpoints. It will also enhance existing store capabilities, allowing for added omnichannel functionality such as store fulfilment. Craig Summers, managing director at Manhattan Associates UK&I, added, "While shopping habits and trends may have changed in recent times, the reputation of New Look as a leading, British fashion brand has remained constant. Manhattan Associates' order management system will enable New Look to integrate to more stock sources and marketplaces, increase visibility of inventory, ship products faster and more profitably from stores and warehouses and offer its customers more of what they want, when and how they want to receive it," Summers ended.

08:34 EDT Assure Holdings appoints Kelly Shelton as VP, sales, Sherri Wagner as VP, HR - Assure Holdings (IONM) announced that Kelly Shelton will join the Company as vice president of sales. In addition, Sherri Wagner was appointed vice president of human resources. As the vice president of sales, Mr. Shelton will oversee revenue-generating activities at Assure including organic sales and channel strategy. He will also play an important role on strategies focused on group purchasing organizations and customer retention. Prior to joining Assure, Mr. Shelton served as vice president at Zimmer Biomet Spine (ZBH) where he led a team that generated more than $500 million in annual sales. Assure has appointed Sherri Wagner as vice president of human resources. Ms. Wagner will play a critical role in supporting the Company's rapid growth and assume responsibility for developing and executing Assure's human resources strategy, including recruiting and retention, learning and development, change management and employee engagement. Prior to joining Assure, Ms. Wagner served as a senior human resources leader at Amazon (AMZN) where she was responsible for launching and staffing a 3.5m square foot fulfillment center.

08:33 EDT GreenPower Motor's vehicles eligible for up to $375,000 in California HVIP Funds - GreenPower Motor Company announced that its purpose-built buses and trucks are eligible for vouchers ranging from $60,000 to $375,000 per vehicle through the California Air Resources Board Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project. The program is scheduled to open at 10 a.m. PT on March 30, with $196,600,000 available in standard HVIP funds; $65,500,000 set aside for public transit; and $122,000,000 set aside for public schools in small and medium air districts. GreenPower's HVIP-eligible models include the company's electric school bus line including the BEAST (Type D) and NanoBeast (Type A); Class 8 transit bus line; and Class 4 EV Star product line, which consists of both cargo trucks and passenger vans.

08:31 EDT ePlus announces 1M share repurchase program - ePlus announced that its board of directors has authorized the company to repurchase up to 1M shares of ePlus' outstanding common stock over a 12-month period commencing May 28. The company's current repurchase plan will expire on May 27. ePlus had approximately 26.89M shares of common stock outstanding as of March 23.

08:28 EDT FINCANNA CAPITAL's QVI adds Royal Greens to distribution team - FinCanna Capital is pleased to announce that its investee company, QVI Inc., operating as West County Brands, has added Royal Greens, an Oakland California based licensed delivery service to its distribution team. Royal Greens has joined FinCanna's sales & marketing partner Petalfast and industry-leading distributor Calyx Brands, to further expand West County Brands distribution footprint in support of its product rollout of its MYTHC Life brand and its joint venture with Cherry Kola Farms, an award-winning producer of premium cannabis products. Delivery service is an essential component of the Company's brand development and retail sales strategy as it is another avenue of meeting consumer demand and increasing sales. Additionally, delivery is increasingly important as there are significant areas of the California market currently underserved by retail dispensaries due to the restrictive nature of certain local regulations regarding dispensary license approvals. Licensed home delivery services like Royal Greens are positioned to reach these underserved markets. Royal Greens serves an area within a 100-mile radius from the city of Oakland and has a client base of more than 20,000 active consumers. Royal Greens is firmly positioned to expand sales of West County Brands' high quality and disruptively priced products, seeing them as an excellent fit for their growing customer base.

08:26 EDT Entourage Health updates timing for Q4, 2021 financials - The Company also announced that it plans to file its fourth quarter and full-year 2021 financial statements and management's discussion and analysis by Tuesday April 26, 2022. Entourage will host a conference call at 10 a.m. Eastern time on April 26th to review the results, provide an operational update, discuss recent milestones and provide more details about the financial performance for the period. Entourage also previously reported preliminary unaudited total revenues of $54.8 million for the fiscal year ended December 31, 2021, an increase of 54 per cent year-over-year, representing a record year of sales growth and expanded market share across its adult-use and medical sales channels.

08:24 EDT Microvast debuts two new lithium ion battery cells, upgraded Gen 4 battery packs - Microvast Holdings announced the introduction of two new lithium ion battery cells to its product portfolio, as well as upgraded Gen 4 battery packs. "The new cells enable our customers to easily optimize vehicle design in terms of energy density and cycle life, delivering improved overall performance and reducing total cost of ownership while preserving fast-charging capabilities. We expect these next generation battery cells to become pivotal revenue drivers for our business going forward," said Mr. Yang Wu, Microvast's President and Chief Executive Officer.

08:23 EDT Real Brands enters medical psychedelics market, partners with Marcu & Arora - Real Brands has entered a partnership with consulting firm Marcu & Arora to apply for U.S. Drug Enforcement Agency, DEA, licensure for psychedelics, including defining the protocols for application and the focus of the formulation research and development. Additionally, Real Brands will apply to the DEA for authorization to process and handle psychedelic substances, and it has applied to the state of Rhode Island to be able to prescribe, dispense, store and ship controlled substances. "We are pursuing research and development of medical psychedelics because current traditional mental health care treatments are often ineffective and have severe negative side effects," stated Thom Kidrin, CEO of Real Brands. "Revolutionary breakthroughs in medicine, pharmacology, and behavioral neuroscience have exposed the vast potential of psychedelics and empathogenic drugs as highly effective therapies. We have engaged Marcu & Arora to help us navigate the complicated process of DEA licensure for research on psychedelics, the protocols for application and all aspects of formulation R&D. We hope to become the first in Rhode Island to secure a license."

08:21 EDT Future plc acquires WhatCulture, Waive, terms not disclosed - Future Plc has continued its rapid expansion with the acquisition of two businesses, WhatCulture, a social-first brand focused on the gaming and entertainment market, and data insight start-up, Waive, which uses machine learning to identify social trends. Together, these acquisitions will bolster Future's diversification of revenue streams, alongside its social media offering, and editorial strategy. Founded in 2006, WhatCulture produces engaging YouTube content for gaming and entertainment audiences. The business brings a wealth of YouTube advertising experience which will further strengthen Future's position in video; with 11 YouTube channels that represent WhatCulture's core method of monetization, attracting more than 8 million subscribers and over 4 billion views. The brand, which sees approximately 70% of its revenue coming from the US, complements Future's existing portfolio of specialist entertainment content. This includes CinemaBlend, which has become the third highest ranked title in Comscore's Entertainment - Movies* category, since its acquisition in 2021. WhatCulture will also benefit from Future's proprietary technology, which will empower greater monetization of its websites and bring efficiencies to its operating model. Future has also acquired data insight company Waive, which uses advanced machine learning to identify and predict trending social topics across Facebook, Twitter, Instagram, YouTube, and Reddit. The intelligent trend spotting platform will empower Future's expert editorial teams to forecast trends, informing the creation of the most engaging content focused on what audiences will care about tomorrow.

08:21 EDT USPS placed its 1st order of 50K NGDV with Oshkosh Defense valued at $2.98B - The U.S. Postal Service announced that it has placed its first order of Next Generation Delivery Vehicles NGDV with Oshkosh Defense, a wholly owned subsidiary of Oshkosh. The initial order is for 50,000 NGDVs and is valued at $2.98B. "We're incredibly proud to build the USPS NGDV. It is designed to be the modern, safe, dependable vehicle the carriers have been waiting for," said John Bryant, Executive Vice President, Oshkosh Corporation, and President, Oshkosh Defense. "Facility preparations in South Carolina are well underway and hiring of team members has already begun." Oshkosh won the competitively awarded NGDV contract in February 2021. Production of the NGDVs is expected to begin in 2023.

08:18 EDT NVR names Eugene Bredow CEO, effective upon Saville's appointment as Chairman - NVR announced that Dwight Schar, Manuel Johnson and William Moran have announced their intention to retire from NVR's Board of Directors and will not stand for re-election at the 2022 Annual Meeting of Shareholders. Messrs. Schar, Johnson and Moran are all original NVR Board members, serving on the Board since 1993. Paul Saville, presently NVR's President and CEO, will stand for election to the Board at the 2022 Annual Meeting of Shareholders. Effective upon his election to the Board, Saville will be appointed Executive Chairman of the Board and will relinquish the President and CEO positions. Saville has been President and CEO of NVR since 2005 and has been employed by NVR since 1981. Saville will continue to provide leadership and strategic direction to NVR as Executive Chairman. The Board has appointed Eugene Bredow as President and CEO effective upon Saville's appointment as Executive Chairman of the Board. Bredow has been employed by NVR since 2004 and has served as President of NVR Mortgage since April 2019. Bredow served as Senior Vice President and Chief Administrative Officer from March 2018 through March 2019. Bredow served as Vice President and Controller from June 2012 and Chief Accounting Officer from February 2016 through February 2018.

08:16 EDT Protara doses first patient in ADVANCED-1 Phase 1 study of TARA-002 - Protara Therapeutics announced that the Company has dosed the first patient in ADVANCED-1, its Phase 1 clinical trial evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer, NIMBC. "NMIBC is one of the most recurrent and difficult to treat cancers with very limited treatment options," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "We are thrilled to have dosed the first patient in our Phase 1 study in NMIBC and look forward to exploring TARA-002's full potential in this pressing area of high unmet need." ADVANCED-1 is a Phase 1 dose-finding, open-label trial evaluating TARA-002 in treatment-naive and treatment-experienced NMIBC patients with high-grade carcinoma in situ, CIS, and high-grade papillary tumors, Ta. In the initial dose escalation phase of the trial, patients will receive six weekly intravesical doses of TARA-002. The primary objective of the trial is to evaluate the safety, tolerability and preliminary signs of anti-tumor activity of TARA-002, with the goal of establishing a recommended dose for a planned Phase 2 clinical trial.

08:14 EDT IMAC initiates third cohort of Phase 1 study of umbilical cord-derived MSCs - IMAC Holdings announces it has initiated the third and final cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson's disease.

08:13 EDT Novo Integrated Sciences PRO-DIP gets U.S. patent for oral pouch delivery system - Novo Integrated Sciences announced that its wholly owned subsidiary, PRO-DIP, was issued U.S. Patent No. 11,273,965 by the U.S. Patent and Trademark Office on March 15. The '965 patent relates to PRO-DIP's novel technology for manufacturing its oral supplement pouches.

08:12 EDT Gain Therapeutics announces upcoming 2022 milestones - Complete the preclinical development and submit the regulatory dossier to the Human Research Ethics Committee in Australia to initiate a first-in-human Phase 1 clinical trial in its GBA1 Parkinson's disease program. Advance its GBA1 Gaucher disease program into regulatory toxicology studies; Announce data from new internally developed allosteric regulator programs; and Continue to progress its research and discovery programs originating from its SEE-Tx platform across a range of indications, including lysosomal storage diseases, genetically driven metabolic disorders and oncology.

08:11 EDT Gain Therapeutics sees cash runway into 2H23 - As of December 31, 2021, the Company's cash position was $36.88 million, compared to $7.49 million as of December 31, 2020.

08:08 EDT Regulus initiates preclinical studies in ALS - Regulus announced the initiation of studies evaluating a library of oligonucleotides designed to block miR-155 for the potential to treat Amyotrophic Lateral Sclerosis - ALS or Lou Gehrig's disease - under a collaboration agreement with the laboratories of Oleg Butovsky and Howard L. Weiner, at Brigham and Women's Hospital - BWH -. The agreement, effective since September 2021, encompasses the investigation of the biologic effects of miR-155 inhibitors in both in vitro and in vivo models of ALS. The study plan focuses on the evaluation of the Regulus-designed compounds that inhibit miR-155 activity in microglia cell-based assays and in animal models of the disease, to identify potential candidates to advance into further studies. Combined, these data will be used in an effort to identify anti-miR-155 lead compounds exhibiting robust pharmacologic profiles and enable their further preclinical therapeutic evaluation and initial testing in subjects with ALS. Preliminary data are expected in the second half of 2022.

08:05 EDT Impel NeuroPharma expects cash to fund operations into 2024 - As of December 31, 2021, Impel had $88.2 million in combined cash, cash equivalents and marketable securities. The Company subsequently closed on a $100 million Royalty and Debt agreement with Oaktree Capital on March 17, 2022. Following closing of this transaction, the Company believes, based on its current operating plan, that it has sufficient capital to fund operations into 2024.

08:04 EDT Joby Aviation resumes flight testing of second pre-production prototype - Joby Aviation announced its second pre-production prototype aircraft has resumed flight testing at the company's pilot production facility in Marina, California. The aircraft first flew in January, having received approval to fly from both the Federal Aviation Administration, or FAA, and the U.S. Air Force. To date, it has made 38 flights, reaching speeds of more than 90 miles per hour, in support of the company's aircraft type certification program. Joby's internal safety review board lifted the company's pause on flight testing earlier this week, which it voluntarily introduced following an accident involving the company's first pre-production prototype earlier this year. Joby continues to work closely with the FAA and National Transportation Safety Bureau to investigate the accident and provides regular briefings on its flight test plans.

08:02 EDT Halozyme, Chugai enter global collaboration, license pact for ENHANZE technology - Halozyme Therapeutics announced a global collaboration and license agreement with Chugai Pharmaceutical Co., Ltd. that gives exclusive access to Halozyme's ENHANZE drug delivery technology, recombinant human hyaluronidase PH20 enzyme, for an undisclosed target. Chugai intends to explore the potential use of ENHANZE for a Chugai drug candidate. Under the terms of the agreement, Chugai will make an upfront payment of $25M to Halozyme and is obligated to make potential future payments of up to $160M in the aggregate, subject to achievement of specified development, regulatory and sales-based milestones. Halozyme will also be entitled to receive royalties on sales of commercialized medicines using the ENHANZE technology.

07:35 EDT Arrowhead files application for clearance to initiate ARO-MUC5AC trial - Arrowhead announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-MUC5AC, the company's investigational RNA interference, or RNAi, therapeutic designed to reduce production of the mucin 5AC, or MUC5AC, as a potential treatment for asthma and various muco-obstructive pulmonary diseases. Arrowhead also announced plans to host a pulmonary R&D day on May 26 to be held in New York and webcast online.

07:29 EDT Alaska Air sees 2022 capacity up 1%-3% compared to 2019 levels - As detailed in the company's fourth quarter 2021 and full-year results, Alaska Air Group's 2022 outlook includes capacity up 1%-3% and CASM ex-fuel up 3%-5% compared to 2019 levels, the company noted ahead of hosting its Investor Day at 11:30 a.m. Eastern time. Alaska plans to grow an average of 4-8% per year through 2025, in part by investing in the depth of its network. "Today, the company will share plans to accelerate the transition of its fleet of 300+ aircraft to all-Boeing 737 for its mainline operations and all-Embraer E175 jets for regional, by the end of 2023. Consistent with Alaska's low-cost high productivity mindset, these transitions are expected to drive significant economic benefits. As the fleet grows to 400 aircraft by mid-decade, these will manifest through operational simplicity, flexibility and scalability, better fuel efficiency and reduced maintenance costs. The company is also growing cargo business operations by converting two passenger 737-800s to freighters, bringing the total freighter fleet to five," the company stated. "Alaska's team is committed to outperforming the industry, even while navigating a choppy pandemic recovery and near-term economic volatility. As people return to travel, they are choosing Alaska. And thanks to the caring spirit of our people, when guests try us, they tend to come back. We are excited for the path ahead and confident in our ability to continue creating value for our employees, guests, communities and shareholders," said Shane Tackett, executive vice president finance and CFO of Alaska Air Group.

07:19 EDT dLocal announces strategic partnership with BigCommerce - DLocal (DLO) announced their strategic partnership with SaaS e-commerce platform BigCommerce (BIGC). Under the new partnership, dLocal will power cross border and local-to-local payments to support BigCommerce's global expansion in Latin America. DLocal's solution enables BigCommerce merchants for the first time to accept localized payments such as local cards and Alternative Payment Methods, including Boleto Bancario and Pix in Brazil, and Oxxo in Mexico. This is the first region where BigCommerce will offer cards and local payment methods.

07:17 EDT Moderna announces clinical, program updates to its mRNA pipeline - Moderna announced clinical and program updates demonstrating expansion and advancement of its mRNA pipeline. This announcement reflects the Company's commitment to expanding its portfolio by building on Moderna's experience with Spikevax, its COVID-19 vaccine. The updates include advancements in the Company's respiratory and latent virus portfolios, updates on its global health programs, and new partnerships formed in the recently launched mRNA Access program. "We believe our mRNA platform disrupts the traditional vaccines market and as indicated in our Vaccines Day announcements, we expect to bring many more safe and effective vaccines to market. There is an opportunity for Moderna to positively impact public and global health, and with 31 active development programs, 19 of which are in the clinic, we expect to address several critical unmet medical needs with the power of our mRNA platform," said Stephane Bancel, Chief Executive Officer of Moderna. Moderna is implementing a multi-pronged approach to ease the substantial global burden of respiratory infections with vaccine candidates aimed at the major causative agents, including the SARS-CoV-2 virus, influenza virus, respiratory syncytial virus, and the four endemic human coronaviruses.

07:15 EDT Calliditas Therapeutics CEO acquires shares through warrant program - Calliditas Therapeutics announced that CEO Renee Aguiar-Lucander has subscribed for 175,000 shares through Calliditas' warrant program 2018/2022. Following the new subscription for shares, Renee Aguiar-Lucander's shareholding in the company will amount to 593,000 common shares. All members of the management team who are warrant holders in the program have today exercised their opportunity to subscribe for shares in the 2018/2022 warrant program, which comprises 856,586 warrants and can be exercised until 31 March 2022. To partially finance the share subscriptions, warrant holders in the program, including the CEO and some members of the management, have sold warrants. The sale of the block, which consisted of the equivalent of 488,000 shares, was made outside the market to a tier one long-term investor.

07:14 EDT Tilray's Solei brand launches new wellness product, Renew Moonlight - Tilray Brands announced the launch of Renew Moonlight a new CBN vape pen designed for nighttime use by wellness brand, Solei. This is a high-CBN vape pen with a potency of 4:1 THC and CBN is blended with citrus and herbal aromas. "Solei products are designed to support daily wellness routines from day to night," said Danielle Minard, Solei, Brand Manager. She continued, "Renew Moonlight is the perfect CBN product for consumers looking to ease into the night after a long day."

07:13 EDT CareDx's AlloCare app integrated with TxAccess - CareDx announced that its AlloCare mobile phone health app, now features a "virtual roadmap" to help patients track and complete the requirements needed to be considered for placement on a transplant waiting list.

07:12 EDT Lucira Health at-home COVID-19 test now available DTC in Canada - Lucira Health announced that its Lucira Check-It COVID-19 test can now be purchased directly by Canadian consumers, businesses, and healthcare providers, available at www.checkit.lucirahealth.ca.

07:11 EDT Lantronix achieves WPA3 Certification for xPico 200 series Wi-Fi IoT gateways - Lantronix announced that its xPico 270, xPico 250 and xPico 240 embedded Wi-Fi IoT gateways have achieved WPA3 Certification for WPA3-Enterprise and WPA3-Personal by the Wi-Fi Alliance.

07:10 EDT BiondVax signs collaborations to develop nanosized antibody therapies - BiondVax has signed definitive agreements with the Max Planck Society, the parent organization of the Max Planck Institute for Multidisciplinary Sciences - MPI -, and the University Medical Center Gottingen - UMG -, both in Germany, to enter into a strategic collaboration for the development of innovative nanosized antibodies - NanoAbs -. BiondVax (BVXV) will have an exclusive option for an exclusive worldwide license at pre-agreed commercial terms for further development and commercialization of each generated NanoAb. The NanoAbs previously developed by BiondVax's collaborators exhibit several valuable competitive advantages over existing therapies including uniquely strong binding affinity, stability at high temperatures, and potential for more effective and convenient routes of administration. The collaboration targets indications with large and growing market sizes where the NanoAb advantages have the potential to capture significant market share such as psoriasis, asthma, macular degeneration, and psoriatic arthritis. NanoAbs can be mass-produced through recombinant protein manufacturing in sites such as BiondVax's GMP biologics manufacturing facility in Jerusalem. Initial preclinical results are expected in 2023. BiondVax anticipates conducting a preclinical proof of concept study of inhaled COVID-19 NanoAbs in 2022 with initial human clinical trials results in 2023. NanoAbs exhibit potential to serve as highly attractive therapies for diseases including COVID-19. NanoAbs are also known as VHH-antibodies or nanobodies. Nanobody is a trademark registered by ABLYNX, a wholly owned subsidiary of Sanofi (SNY). BiondVax has no affiliation with and is not endorsed by Sanofi.

07:09 EDT GURU Organic Energy launches Made with Plants campaign - GURU Organic Energy announces the launch of Made with Plants, a national campaign that highlights GURU's market position as the only plant-based drink in its category, and introduces Guayusa Tropical Punch to Canadians from coast to coast after its launch in Quebec in late 2021. Developed in collaboration with Sid Lee, the 6-week integrated, omnichannel campaign will kick off at the end of March. It features GURU's full line-up of energy drinks and focuses on one of GURU's key differentiators: its entirely plant-based and organic list of ingredients. The campaign will also be supported by the first large-scale in-store activation program, with the support of GURU's exclusive Canadian distributor.

07:09 EDT Darden reports Q3 blended same-restaurant sales up 38.1% - Q3 same-restaurant sales by segment: Consolidated Darden 38.1%; Olive Garden 29.9%; LongHorn Steakhouse 31.6%; Fine Dining 85.8%; Other Business 55.2%. "This was a quarter of stark contrasts and I'm pleased with our performance in this highly volatile environment," said Chairman and CEO Gene Lee. "It began with record sales in December. However, the Omicron variant significantly impacted guest demand, restaurant staffing and operating expenses in January. I am proud of the job our restaurant teams did managing through a difficult operating environment. They remained focused on executing at the highest level and delivered strong sales in February as the environment improved." "Darden is well positioned to compete effectively," Lee continued. "We have a strong balance sheet and the right strategy in place, driven by our four competitive advantages of significant scale, extensive data and insights, rigorous strategic planning and our results-oriented culture. And, our brands are relentlessly focused on executing our back-to-basics operating philosophy anchored in food, service and atmosphere."

07:06 EDT Hookipa Pharma announces upcoming milestones - Phase 1 HPV16+ monotherapy data: Mid-2022, Phase 2 HPV16+ combination data in HNSCC, 1st-line initial data: 2H 2022, 2nd-line initial data: 2H 2022, Randomized Phase 2 in 1st line start with pembrolizumab: 1H 2023, Prostate cancer IND: 3Q 2022, Hepatitis B therapeutic IND: 2022

07:05 EDT Apellis announces pricing of public offering of common stock - Apellis Pharmaceuticals announced the pricing of its underwritten public offering of 7,446,809 shares of its common stock at a public offering price of $47.00 per share, for total gross proceeds of $350 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. All of the shares in the offering are being sold by Apellis. In addition, Apellis has granted the underwriters a 30-day option to purchase up to 1,117,021 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on March 28, 2022, subject to customary closing conditions. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C. are acting as joint book-running managers for the offering. Raymond James & Associates, Inc. is acting as lead manager and Oppenheimer & Co. Inc. and Robert W. Baird & Co. Incorporated are acting as co-managers for the offering.

07:04 EDT Alaska Air and Bank of America renew co-branded credit card partnership - Alaska Air (ALK) and Bank of America (BAC) announced an extension of their co-branded credit card agreement through 2030. Alaska Airlines' co-branded credit card with Bank of America currently offers cardholders a loyalty rewards program including Alaska's Famous Companion Fare, free checked bag, the opportunity to earn 3x the miles on eligible Alaska purchases, oneworld Alliance mile redemptions, 50% discount on day passes for Alaska Lounge access, 20% back on all inflight purchases and other travel benefits. In the second half of 2022, Alaska and Bank of America intend to announce additional benefits to further elevate its loyalty program for cardholders.

07:03 EDT NextDecade executes HOA with Guangdong Energy for long-term LNG supply - NextDecade announced the execution of a binding heads of agreement, or HOA, with Guangdong Energy for the long-term supply of liquefied natural gas, or LNG, for 20 years from NextDecade's Rio Grande LNG export project in Brownsville, Texas. The HOA provides that Guangdong Energy will purchase up to 1.5M tons per annum of LNG indexed to Henry Hub. The LNG supply will initially be from train one of Rio Grande LNG, which is expected to start commercial operations in 2026. The HOA also provides that Guangdong Energy and NextDecade will complete the sale and purchase agreement in the second quarter of 2022.

06:53 EDT KULR Technology wins additional Department of Defense contractors - KULR Technology secured three additional contracts with United States Department of Defense prime contractors implementing its carbon fiber cathode solution for high power magnetic and other covert pulse weaponry initiatives. KULR's carbon fiber configuration provides the conduit for transference of high-power electron pulses generated via field emission throughout the carbon fiber architecture.

06:51 EDT Movado increases quarterly dividend 40% to 35c per share - Movado approved a 40% increase to the regular quarterly cash dividend to 35c per share from 25c per share. A 35c dividend will be paid on April 20 for each share of the company's outstanding common stock and class A common stock held by shareholders of record as of the close of business on April 6.

06:50 EDT Eli Lilly receives CRL from FDA stating it is not able to approve sintilimab BLA - Eli Lilly announced that the FDA has issued a complete response letter, or CRL, for the biologics license application, or BLA, for the investigational medicine sintilimab injection, a PD-1 inhibitor in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer, or NSCLC. Sintilimab is being developed by Innovent Biologics and Lilly. The letter indicates that the review cycle is complete but the FDA is unable to approve the application in its current form, consistent with the outcome of the Oncologic Drugs Advisory Committee Meeting in February. The CRL includes a recommendation for an additional clinical study, specifically a multiregional clinical trial comparing standard of care therapy for first line metastatic NSCLC to sintilimab with chemotherapy utilizing a non-inferiority design with an overall survival endpoint. Along with Innovent, Lilly is assessing next steps for the sintilimab program in the U.S.

06:47 EDT EU commercial vehicle registrations down 15.7% in February - In February, new commercial vehicle registrations retreated across the European Union, down 15.7% to 131,874 units, reported the European Automobile Manufacturers Association. Except for heavy commercial vehicles, all segments recorded declines, the group said. Publicly traded truck makers and suppliers include Daimler AG (DDAIF), Paccar (PCAR), CNH Industrial (CNHI), Navistar (NAV), Cummins (CMI) and Allison Transmission (ALSN).

06:30 EDT China Online Education gets proposal from CEO to acquire mainland china business - China Online Education has received a non-binding proposal letter from Jiajia Jack Huang, chairman of the board and chief executive officer of the company, stating that "considering the increasingly stringent restrictions of the applicable PRC laws and regulations on the business of the Company and the adverse effect arising from it," he proposed to acquire all of the company's businesses in China Mainland, including all associated liabilities and assets. Such businesses include K-12 English lessons taught by foreign teachers, all-round proficiency lessons taught by Chinese teachers, and post-secondary English lessons taught by foreign teachers, by acquiring all of the equity interests of China Online Education limited, its subsidiaries and the variable interest entities controlled by the company. The proposed purchase price for the target companies is $1 because Mr. Huang believes that the total enterprise value of the target companies is equivalent to the existing total liabilities and obligations of the target companies. The company's overseas business outside China Mainland and its associated liabilities and assets are not part of the proposed transaction and will be the company's strategic focus going forward. The Board has formed a special committee to evaluate the proposed transaction. The special committee includes Mr. Roy Rong and Mr. Xiaoguang Wu, both independent directors. Mr. Roy Rong was appointed the chairman of the special committee by the Board.

06:16 EDT AstraZeneca's Imfinzi phase 3 trial did not achieve primary endpoint - The company states: "The CALLA Phase III trial for AstraZeneca's Imfinzi, or durvalumab, given concurrently with chemoradiotherapy, CRT, did not achieve statistical significance for the primary endpoint of improving progression-free survival versus CRT alone in the treatment of patients with locally advanced cervical cancer." Reference Link

06:12 EDT Fat Brands CEO addresses federal investigation in earnings call - Fat Brands CEO Andrew Wiederhorn said on the company's earnings call this week that "given my personal history it does not surprise me that the government will look into allegations." He said that "being a public company and a public figure attracts its share of visibility." It was disclosed last month that the federal government is investigating him and his family for alleged financial crimes. Wiederhorn said the legal matters are a "distraction personally," as it focuses "on me and my family," but that the Fat Brands team is focused on running the business.

06:02 EDT Fennec resubmits NDA to FDA for Pedmark - Fennec Pharmaceuticals announced the resubmission of its New Drug Application to the U.S. FDA for Pedmark for the prevention of platinum-induced ototoxicity in pediatric patients one month to less than18 years of age with localized, non-metastatic, solid tumors. "We appreciate the FDA's comments during the resubmission process and look forward to working closing with the Agency during the NDA review," said Rosty Raykov, CEO of Fennec Pharmaceuticals. "We are pleased to have reached this important step and Fennec remains committed to making Pedmark available to reduce the risk of cisplatin induced ototoxicity in pediatric patients."

05:17 EDT Molecular Partners publishes preclinical MP0317 data - Molecular Partners announced the publication of preclinical data from MP0317 in Cancer Immunology Research, a journal of the American Association for Cancer Research. MP0317 is the company's second immuno-oncology program to enter clinical studies and is designed to target both FAP, a protein found in high density around tumors, and the immunostimulatory protein CD40, to enable tumor-localized immune activation. Administration of CD40-targeting monoclonal antibodies has challenges with achieving a meaningful clinical response. Low concentrations result in minimal efficacy, but higher concentrations rapidly lead to systemic toxicity, limiting the therapeutic window achievable with systemic CD40 activation. The DARPin therapeutic candidate MP0317 is designed to specifically induce CD40-mediated immune activation only in the FAP-rich local tumor environment, preventing systemic immune activation. The published study confirms that MP0317 is inducing FAP-dependent CD40-mediated B and myeloid cell activation, thus supporting the candidate intended mechanism of action of tumor-localized immune activation without the systemic toxicity observed with other CD40-targeting agents. This study suggests that MP0317, as a DARPin therapeutic candidate, has the potential for a broader therapeutic window and thus improved clinical activity compared to CD40 agonist antibodies. The publication can be found in this link. MP0317 is currently being tested in a Phase 1 clinical trial sponsored by the company. The open-label dose escalation study is designed to assess the safety and tolerability as well as pharmacokinetics and pharmacodynamics of MP0317 as a monotherapy in patients with solid tumors known to express FAP. In addition to evaluating monotherapy dynamics, the study will gather biomarker data to support the establishment of combination studies of MP0317 with other therapies in specific indications. Initial data from the ongoing Phase 1 clinical trial are expected in the second half of 2022.

05:08 EDT Paysafe enters payments partnership with Resorts WorldBET - Paysafe announced a partnership with Resorts WorldBET, the new mobile sports-betting app for Resorts World New York, with brick-and-mortar casinos Resorts World Catskills, or RWC, and Resorts World New York City, or RWNYC. Already facilitating payments for multiple New York mobile sportsbooks since the market's launch in January, Paysafe now enables players to make deposits with Resorts WorldBET by debit card and ACH, plus receive payouts.

05:05 EDT Compass Pathways, partners to launch psychedelic research facility - Compass Pathways has formed a long-term strategic partnership to launch The Centre for Mental Health Research and Innovation to accelerate psychedelic research and develop new models of care for mental health in the UK. The Centre will accelerate research of emerging psychedelic therapies, support therapist training and certification, evaluate real-world evidence, and prototype digital technologies to enable personalized, predictive and preventative care models.